https://www.selleckchem.com/pr....oducts/bay-2666605.h
Here, using aggressive triple-negative and HER2-positive human breast cancer cell lines as models, we report that MitoQ inhibits all the metastatic traits that we tested in vitro. Compared to other mitochondria-targeted antioxidants, MitoQ already successfully passed Phase I safety clinical trials, which provides an important incentive for future preclinical and clinical evaluations of this drug for the prevention of breast cancer metastasis.Intraoperative radiotherapy (IORT) of the operative cavity for surgically treated brain meta
Curtir
Comentario
Compartilhar
